Prime Medicine, Inc. Common Stock (PRME)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $949.85M
Last updated: Nov 17, 2026 at 11:06 AM ET
Prime Medicine, Inc. Common Stock (PRME) Stock Forecast
Analysts expect Prime Medicine, Inc. Common Stock (PRME) to earn -$0.96 per share in the fiscal year ending Dec 31, 2026, on revenue of $9.31M. Of 14 analysts, 11 rate the stock Buy or Strong Buy, 3 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 7 estimates for the fiscal year ending Dec 31, 2026 were revised up and 3 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 14 ratings average 2.14, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 79% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 7.1% |
| Buy | 10 | 71.4% |
| Hold | 3 | 21.4% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 14
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 26.7%.
- Fiscal year ending Dec 31, 2026
- -$0.96
- EPS consensus, revenue $9.31M
- Fiscal year ending Dec 31, 2027
- -$0.88
- EPS consensus, revenue $11.80M
- Next report
- Mar 1, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.96 | -$0.96 to -$0.95 | 3 | $9.31M | $2.01M to $53.01M | 12 |
| Dec 31, 2027 | -$0.88 | -$1.22 to -$0.67 | 12 | $11.80M | N/A | 11 |
Quarterly Estimates
The EPS consensus falls from -$0.23 for the quarter ending Dec 31, 2026 to -$0.26 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.23 | -$0.31 to -$0.04 | 17 | $2.40M | N/A | 14 |
| Mar 31, 2027 | -$0.26 | -$0.35 to -$0.19 | 6 | $1.09M | N/A | 5 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 11 upward and 8 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 7 | 3 |
| Fiscal year ending Dec 31, 2027 | 3 | 5 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.95.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.96 | -$0.95 | -$0.94 | -$0.93 | -$0.95 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.88 | -$0.90 | -$0.89 | -$0.88 | -$0.86 | N/A |
| Quarter ending Mar 31, 2027 | -$0.26 | -$0.26 | -$0.26 | -$0.26 | -$0.30 | N/A |
Frequently Asked Questions About PRME
What is the PRME stock forecast?
Consensus analyst estimates put Prime Medicine, Inc. Common Stock's EPS at -$0.96 for the fiscal year ending Dec 31, 2026, on revenue of $9.31M. The consensus rating from 14 analysts is Buy.
How do analysts rate PRME stock?
Of 14 analysts covering Prime Medicine, Inc. Common Stock, 1 rates it Strong Buy, 10 Buy, 3 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from PRME next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.96, with estimates from -$0.96 to -$0.95 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.88, with estimates from -$1.22 to -$0.67 from 12 analysts.
What revenue do analysts expect from Prime Medicine, Inc. Common Stock next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $9.31M, with estimates from $2.01M to $53.01M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $11.80M.
How many analysts cover PRME?
14 analysts rate Prime Medicine, Inc. Common Stock stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
PRME pages: Overview, Earnings, Forecast, Financials, Competitors